Latest Blogs, Articles, and More
The Food and Drug Administration (FDA) has granted a priority review to Opdivo for use in patients with previously treated, advanced, squamous non-small cell lung cancer (NSCLC). A decision will be made by June 22, 2015.
Now that the big day has arrived, what happens next? It may not be as exciting as advertised.
The management of patients with hormone receptor (HR)-positive breast cancer continues to evolve, with phase 3 studies shedding light on the length of adjuvant anti-estrogen therapy, a novel treatment gaining approval, and new trials exploring combination strategies.
Metastatic breast cancer will strike 30% of all breast cancer survivors yet only 2% of funds go to research this deadly cancer.
Being offered the chance to be an inspiration isn't up to you. What you do with it afterwards, is.